Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension

Richmond Pharmacology contributed 98 of the 124 patients enrolled in this study, five times more than the next site in terms of recruitment. We are proud of our extraordinary contribution to this study, all achieved during the confines of a global pandemic. Our dedicated team of physicians and researchers worked tirelessly during this time to bring about a potential breakthrough in the treatment of hypertension.

Zilebesiran data was previously presented at the American Heart Association (AHA)Scientific Sessions in November 2021 : Alnylam Pharmaceuticals Press Release | Nov 13, 2021 | Alnylam Presents New Data for Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension.

Hypertension (high blood pressure) affects over 1 billion patients globally, posing serious health risks. Hypertension is a major risk factor for ischemic heart disease, stroke, and chronic kidney disease and is the leading preventable factor in death from cardiovascular causes worldwide.

We are thrilled to share this important research that could potentially revolutionize hypertension management.  The New England Journal of Medicine's recognition is a testament to the importance and impact of this research.

We invite you to read the full article in the New England Journal of Medicine to delve into the details of the trial. Discover how Zilbesiran, this innovative anti-hypertensive injectable, may pave the way for more effective, targeted approaches to blood pressure management.